Phylogenic analyses revealed linear evolution in 18 of 19 patients whose longitudinal samples were successfully processed, indicating a genetic landscape that does not change markedly over treatment time course and is dominated by truncal clones harboring alterations of TP53 and RB1. Prior studies have also reported low subclonal diversity in SCLC [23, 78]. Here, TP53 is linked to small cell lung carcinoma.